HIV vaccine passes first safety test in infants

NCT ID NCT04607408

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tested an experimental HIV vaccine in 38 healthy infants born to HIV-positive mothers. The vaccine was designed to teach the immune system to recognize HIV. The main goal was to see if it was safe and whether it triggered an immune response. The study is complete, but results are not yet public.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

HIV-1 CH505 transmitted/founder gp120 protein vaccine with GLA-SE adjuvant

What this could lead to

If it works, this could point toward a safe vaccine to protect infants from HIV infection.

What could go wrong

This is a very early phase 1 trial with only 38 infants, so it cannot prove the vaccine prevents HIV. It only tested safety and basic immune response.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Perinatal HIV Research Unit (PHRU), Soweto CRS

    Johannesburg, Gauteng, 1862, South Africa